Ordering Recommendation

Optimize drug therapy and monitor patient adherence.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.

Collect

Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2 EDTA).

Specimen Preparation

Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).

Remarks
Stability

After separation from cells: Ambient: 1 week; Refrigerated: 1 week; Frozen: 6 weeks

Methodology

Quantitative Enzyme Multiplied Immunoassay Technique

Performed

Sun-Sat

Reported

1-4 days

Reference Interval

Effective February 19, 2013

Therapeutic Range Not well established
Toxic Level Greater than 80 µg/mL

Interpretive Data

The proposed therapeutic range for seizure control is 10-40 µg/mL. Toxic concentrations may cause coma, seizures and cardiac abnormalities. Pharmacokinetics varies widely, particularly with co-medications and/or compromised renal function.

Compliance Category

FDA

Note

Hotline History

N/A

CPT Codes

80203

Components

Component Test Code* Component Chart Name LOINC
0097908 Zonisamide Quantitative 29620-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Excegran
  • Zonegran
  • zonegran blood level
  • zonegran concentration
  • zonisamide blood concentration
Zonisamide